EHC and EUPATI Partner to Advance Patient Education and Engagement in Therapeutic Innovation
The European Haemophilia Consortium (EHC) recently shared an announcement post on X:
”EHC has partnered with The European Patients’ Academy on Therapeutic Innovation to enhance education and research for European Patients. Together, we’ll strengthen the voice of the rare Bleeding Disorders community & improve outcomes across Europe.”
To read more, follow the link.
European Haemophilia Consortium has announced a new partnership with the European Patients’ Academy of Therapeutic Innovation (EUPATI), a nonprofit foundation dedicated to educating patients and the public on the medicine development process.
Representing over 120,000 individuals with rare bleeding disorders, the Consortium brings deep patient insight and multi-stakeholder collaboration to the alliance.
This partnership reflects both organizations’ shared commitment to empowering patients and strengthening the role of informed, engaged communities in shaping the future of healthcare.
Learn about the latest major collaborations in the field of Rare Diseases with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis